This article reviews NEAR's historical price movements and market fluctuations, analyzing returns for investors buying 10 tokens across various phases from 2020 to 2025, ultimately addressing the question of whether to invest in NEAR now.

Oracle CEO Larry Ellison's net worth surged to #1 globally following a significant earnings increase. His stakes in Oracle, Tesla, and Paramount Skydance illustrate his influence across technology, electric vehicles, and media, raising questions about investment strategies.

Buffett's steadfast $50B investment in American Express reveals confidence in its strong performance, with 2024 revenues up 9% and a robust shareholder return. Despite risks like recession and competition, AmEx's double-digit growth and attractive valuation compared to Apple and Alphabet suggest significant long-term potential.

U.S. durable goods orders fell 2.8% in July, better than the expected 4.0% drop, primarily due to a significant decline in transportation equipment. Excluding transportation, core orders rose 1.1%, indicating underlying strength in manufacturing.

Cipher Mining (CIFR) has surged 209.5% YTD, outperforming competitors. Despite promising revenue growth and major contracts, concerns about high valuation and Bitcoin price dependency raise caution among analysts. A "Hold" rating suggests waiting for better entry opportunities.

Altria's tightened 2025 EPS guidance signals potential margin growth issues, with cigarette market share losses and promotional spending in oral tobacco impacting margins. Competitors like Philip Morris are outperforming, leading to a 10% drop in Altria's stock. Future growth looks uncertain.

Lilly ( LLY )'s stock price just broke through $1000/share in November, with a market capitalization approaching $1 trillion. Everyone knows that Mounjaro ( diabetes ) and Zepbound ( weight loss ) are the two GLP-1 miracle drugs supporting its stock price, but in fact, Lilly's growth engine is far from just these.
Newly approved drugs have contributed real gold and silver.
The latest financial report shows that Eli Lilly's new drug sales are quite impressive in the first nine months of 2025:
- Jaypirca( Hematologic malignancies ): $358 million
- Ebglyss( skin disease ): 274 million USD
- Omvoh( Inflammatory Bowel Disease): $177 million
- Kisunla( Alzheimer's disease ): $141 million
These drugs are also expanding into multiple indications, such as Ebglyss currently undergoing Phase III clinical trials for rhinitis, hay fever, and more diseases. Kisunla has already been in Europe.

KO has posted strong YTD gains but trades at a premium P/E ratio. Despite its market dominance and innovative campaigns, earnings growth estimates are modest. Meanwhile, competitors like PepsiCo show greater diversification. The debate centers on whether KO's valuation reflects its brand strength or if higher growth potential can be found elsewhere.

This report details the current exchange rate of the Saudi Riyal (SAR) against the West African CFA Franc (XOF), offering insights on market dynamics and highlighting trading strategies based on recent trends and fluctuations.

Woodside Energy has partnered with Timor-Leste to develop a large LNG project in the Greater Sunrise gas fields, targeting first LNG production between 2032-2035, with future potential for regional energy supply amidst global gas demand.

Comcast faces a dire future, with 65% of its revenue declining due to saturated broadband and a mass exodus from cable TV. Competing against well-funded rivals, its stock has plummeted, revealing significant weaknesses in both fundamentals and technicals.